T-cells with a single tumor antigen-specific T-cell receptor can be generated in vitro from clinically relevant stem cell sources.
Ontology highlight
ABSTRACT: Chimeric antigen receptor (CAR) T-cells have shown great promise in the treatment of B-cell malignancies. For acute myeloid leukemia (AML), however, the optimal target surface antigen has yet to be discovered. Alternatively, T-cell receptor (TCR)-redirected T-cells target intracellular antigens, marking a broader territory of available target antigens. Currently, adoptive TCR T-cell therapy uses peripheral blood lymphocytes for the introduction of a transgenic TCR. However, this can cause graft-versus-host disease, due to mispairing of introduced and endogenous TCR chains. Therefore, we started from hematopoietic stem and progenitor cells (HSPC), that do not express a TCR yet, isolated from healthy donors, patients in remission after chemotherapy and AML patients at diagnosis. Using the OP
SUBMITTER: Bonte S
PROVIDER: S-EPMC7028335 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature
ACCESS DATA